secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K/A
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001437749-24-016162
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports Q1 2024 results; Annamycin shows 62% CRc in 1st/2nd line AML
------------------------------------------------------------------------------

- R&D expense $4.3M, G&A $2.4M; cash $16.8M sufficient into Q4 2024.
- MB-106 interim data: CRc 62% (54% CR) in 1st/2nd line AML (N=13).
- All lines CRc 45% across 20 subjects; median durability 4.9 months and climbing.
- Milestones: complete MB-106 H1 2024; EOP2 meeting H1 2024; pivotal trial H1 2025.
- Received EMA Orphan Drug Designation for Annamycin in AML; U.S. patents issued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774924016162/0001437749-24-016162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774924016162/mbrx20240513_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer